Company Causality vs. Regulatory/Reporter Causality

A single case almost always carries more than one causality assessment, and understanding why — and how they relate to each other — matters more than it might first appear. The original reporter, often the treating physician, forms their own impression of whether the drug caused the event, informed by direct clinical contact with the patient that the company processing the case afterward simply doesn’t have. The company then performs its own, separate causality assessment, informed by the full case as documented, the drug’s known safety profile, and consistency with how similar cases have been assessed elsewhere in the safety database.

These two assessments can legitimately diverge, and that’s not a sign either one is wrong. A treating physician assessing in real time, with direct access to the patient, may weigh clinical intuition heavily; a company medical reviewer working from the documented case, without that direct contact, may weigh the documented evidence against the drug’s established profile differently. Different scales, different available information, and different institutional vantage points all contribute to genuine, defensible disagreement.

What matters operationally is that neither assessment simply overwrites the other — both get recorded in the case, distinctly labelled as the reporter’s assessment and the company’s assessment. And for expedited regulatory reporting purposes specifically, the more cautious of the two typically governs: if either the reporter or the company considers the case possibly related, it’s treated as suspected for the purposes of determining whether expedited reporting timelines apply, regardless of which assessment was more cautious. This is a deliberate, patient-safety-oriented design choice — it means a company can’t use its own more conservative causality assessment to avoid an expedited reporting obligation the reporter’s assessment would have triggered.

This dual-assessment structure is also why a compliant narrative, as covered in Module 5, explicitly states both the reporter’s causality statement and the company’s — a reviewer needs to see both, not a single blended conclusion, to understand the full picture of how the case was actually assessed and by whom.